• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

tetano

Editor, Senior Moderator
Cell Rep


. 2022 Dec 14;111903.
doi: 10.1016/j.celrep.2022.111903. Online ahead of print.
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75


Jiandong Huo[SUP] 1 [/SUP], Aiste Dijokaite-Guraliuc[SUP] 2 [/SUP], Chang Liu[SUP] 3 [/SUP], Daming Zhou[SUP] 4 [/SUP], Helen M Ginn[SUP] 5 [/SUP], Raksha Das[SUP] 2 [/SUP], Piyada Supasa[SUP] 2 [/SUP], Muneeswaran Selvaraj[SUP] 2 [/SUP], Rungtiwa Nutalai[SUP] 2 [/SUP], Aekkachai Tuekprakhon[SUP] 2 [/SUP], Helen M E Duyvesteyn[SUP] 6 [/SUP], Alexander J Mentzer[SUP] 7 [/SUP], Donal Skelly[SUP] 8 [/SUP], Thomas G Ritter[SUP] 9 [/SUP], Ali Amini[SUP] 10 [/SUP], Sagida Bibi[SUP] 11 [/SUP], Sandra Adele[SUP] 9 [/SUP], Sile Ann Johnson[SUP] 9 [/SUP], Neil G Paterson[SUP] 5 [/SUP], Mark A Williams[SUP] 5 [/SUP], David R Hall[SUP] 5 [/SUP], Megan Plowright[SUP] 12 [/SUP], Thomas A H Newman[SUP] 12 [/SUP], Hailey Hornsby[SUP] 13 [/SUP], Thushan I de Silva[SUP] 12 [/SUP], Nigel Temperton[SUP] 14 [/SUP], Paul Klenerman[SUP] 15 [/SUP], Eleanor Barnes[SUP] 15 [/SUP], Susanna J Dunachie[SUP] 16 [/SUP], Andrew J Pollard[SUP] 17 [/SUP], Teresa Lambe[SUP] 18 [/SUP], Philip Goulder[SUP] 19 [/SUP]; OPTIC consortium; ISARIC4C consortium; Elizabeth E Fry[SUP] 20 [/SUP], Juthathip Mongkolsapaya[SUP] 21 [/SUP], Jingshan Ren[SUP] 22 [/SUP], David I Stuart[SUP] 23 [/SUP], Gavin R Screaton[SUP] 24 [/SUP]



Affiliations
Free PMC article

Abstract

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused successive global waves of infection. These variants, with multiple mutations in the spike protein, are thought to facilitate escape from natural and vaccine-induced immunity and often increase in affinity for ACE2. The latest variant to cause concern is BA.2.75, identified in India where it is now the dominant strain, with evidence of wider dissemination. BA.2.75 is derived from BA.2 and contains four additional mutations in the receptor-binding domain (RBD). Here, we perform an antigenic and biophysical characterization of BA.2.75, revealing an interesting balance between humoral evasion and ACE2 receptor affinity. ACE2 affinity for BA.2.75 is increased 9-fold compared with BA.2; there is also evidence of escape of BA.2.75 from immune serum, particularly that induced by Delta infection, which may explain the rapid spread in India, where where there is a high background of Delta infection. ACE2 affinity appears to be prioritized over greater escape.

Keywords: ACE2 receptor; BA.2.75; COVID-19; CP: Immunology; CP: Microbiology; RBD; SARS-CoV-2; antigenic variation; immune escape; spike; variant; variant of concern.
 
Back
Top Bottom